Literature DB >> 2833367

Effect of cholecystokinin on pancreatic carcinogenesis in the hamster model.

P M Pour1, T Lawson, S Helgeson, T Donnelly, K Stepan.   

Abstract

To examine the effect of cholecystokinin (CCK) on pancreatic carcinogenicity in the hamster model, two sets of experiments were carried out. In one study, CCK (20 IDU/kg body wt) was given 3 h before, simultaneously with or 3 h after a single dose (20 mg/kg body wt) of N-nitrosobis(2-oxopropyl)amine (BOP). In another experiment, hamsters were treated similarly except that both CCK (20 IDU/kg body wt) and BOP (2.5 mg/kg body wt) were given weekly for 20 weeks. The results showed that CCK in the first experiment (single BOP dose) inhibited pancreatic cancer induction in a statistically significant fashion when given either 3 h prior to (P less than 0.05) or simultaneously with BOP (P less than 0.0005); however, CCK, when administered after BOP did not alter the cancer incidence as compared with hamsters treated with BOP alone. In the second experiment (chronic BOP treatment) the pattern and the incidence of pancreatic tumors were not affected by CCK.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2833367     DOI: 10.1093/carcin/9.4.597

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  9 in total

Review 1.  The activation of beta-substituted nitrosamines that are carcinogenic to the pancreas.

Authors:  T Lawson; D Nagel; D Rogers
Journal:  Int J Pancreatol       Date:  1991-09

Review 2.  Cancer of the pancreas.

Authors:  D C Carter
Journal:  Gut       Date:  1990-05       Impact factor: 23.059

Review 3.  Perspectives of CCK antagonists in pancreatic research and clinical use. Part I.

Authors:  L C Rovati
Journal:  Int J Pancreatol       Date:  1991-04

Review 4.  On the role of cholecystokinin in pancreatic cancer.

Authors:  M K Herrington; T E Adrian
Journal:  Int J Pancreatol       Date:  1995-04

Review 5.  Gastrointestinal hormones as potential adjuvant treatment of exocrine pancreatic adenocarcinoma.

Authors:  W E Fisher; P Muscarella; L G Boros; W J Schirmer
Journal:  Int J Pancreatol       Date:  1998-12

Review 6.  Biology of pancreatic cancer.

Authors:  G J Poston; J Gillespie; P J Guillou
Journal:  Gut       Date:  1991-07       Impact factor: 23.059

7.  Enhancement of biliary carcinogenesis in hamsters by cholecystokinin.

Authors:  Y Ikematsu; T Tomioka; Y Tajima; T Tsunoda; T Kanematsu
Journal:  World J Surg       Date:  1995 Nov-Dec       Impact factor: 3.352

8.  Role of cholecystokinin in dietary fat-promoted azaserine-induced pancreatic carcinogenesis in rats.

Authors:  M J Appel; M Meijers; A Van Garderen-Hoetmer; C B Lamers; L C Rovati; D Sprij-Mooij; J B Jansen; R A Woutersen
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640

9.  Inhibitory effect of a cholecystokinin antagonist on pancreatic carcinogenesis after pancreatobiliary diversion.

Authors:  P Watanapa; B Flaks; H Oztas; P H Deprez; J Calam; R C Williamson
Journal:  Br J Cancer       Date:  1993-04       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.